Is AbbVie (ABBV) a risky stock?
As of July 21, 2026, Clavix grades AbbVie (ABBV) B for risk, a composite score of 71 out of 100 on an A+ to F scale, which puts ABBV in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ABBV's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ABBV scores on each, as of July 21, 2026.
What's moving ABBV's risk right now
Company-specific signals Clavix flags behind ABBV's current grade, drawn from recent news and filings as of July 21, 2026.
Income-focused investors likely have little reason to worry about a dividend cut; AbbVie's free cash flow should comfortably absorb the Apogee deal while sustaining its long-stand…
Earnings are roughly in line with expectations, providing little catalyst in either direction.
What a B grade means
On the Clavix A+ to F scale, ABBV's composite of 71 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ABBV or any security. Grades are risk indicators, not predictions of return. Data may be delayed.